BRAF and melanoma: The YAP1 inhibitor Verteporfin is efficient in preclinical models of kidney fibrosis [134] and it has been exploited as a molecular target in a pre-clinical model of melanoma, where it prevents the fibrotic phenotype induced by oncogenic BRAF inhibition [12].